| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 26 Feb 2025 | 26 Feb 2025 |
| Outcome of Board Meeting - 26th February 2025 | ||
| Board Meeting | 3 Feb 2025 | 16 Jan 2025 |
| Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2025 inter alia to consider and approve Unaudited financial results for the quarter and nine months ended 31.12.2024 Unaudited Financial Results for the Quarter ended December 31, 2024 (As Per BSE Announcement Dated on: 03/02/2025) | ||
| Board Meeting | 4 Nov 2024 | 22 Oct 2024 |
| Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2024 inter alia to consider and approve Unaudited Financial results for the quarter and Half year ended September 30 2024 Appointment of Ms. Wei Huang as Additional Director w.e.f November 04, 2024 (As per BSE Announcement Dated on 04/11/2024) | ||
| Board Meeting | 6 Aug 2024 | 19 Jul 2024 |
| Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2024 inter alia to consider and approve Un-Audited Financial Results for the Quarter ended June 30 2024 Unaudited Financial Results for Q1 FY25 (As Per BSE Announcement dated on 06.08.2024) | ||
| Board Meeting | 7 Jun 2024 | 7 Jun 2024 |
| Outcome of the Board Meeting held on June 07, 2024 | ||
| Board Meeting | 22 May 2024 | 9 May 2024 |
| Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 inter alia to consider and approve Audited Financial Results for the quarter and financial year ended 31.03.2024 and to consider and recommend the payment of Final Dividend for FY 2023-24 Outcome of Board Meeting held on May 22, 2024 (As per BSE Announcement Dated on 22/05/2024) | ||
Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US
The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.
Here are some of the stocks that may see significant price movement today: Tata Chemicals, Power Grid, Welspun Enterprises, etc.
EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortization) increased by 1% YoY to ₹360 crore, compared to ₹356.4 crore in the previous year.
Sintilimab is marketed in China as TYVYT (sintilimab injectable) and was co-developed by Innovent and Eli Lilly.
Here are some of the stocks that may see significant price movement today: Power Mech, IndiGo, NHPC, Gland Pharma, etc.
Gland Pharma stock has gained a total of 12% in the last one year, and 7.37% dip since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Power, Chambal Fertilisers, Cummins India, etc.
The inspection concluded with three 483 observations. Gland Pharma clarified that these observations are procedural and not related to data integrity or repeat issues.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
